Drosophila Sequenced--Now the Tricky Part

Celera Genomics announced Sept. 9 that the Rockville, Md., company had sequenced the 1.8 billion base pairs that make up the Drosophila melanogaster genome. Now comes the tricky part--putting them together to form an accurate, contiguous fruit fly genome. "The sequence data is good," Paul Gilman, a Celera vice president, claims. "The question is, 'How good is our assembly?'" That's a question that critics of the company's "whole genome shotgun" sequencing approach--blasting the entire genome in

Written byPaul Smaglik
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Celera Genomics announced Sept. 9 that the Rockville, Md., company had sequenced the 1.8 billion base pairs that make up the Drosophila melanogaster genome. Now comes the tricky part--putting them together to form an accurate, contiguous fruit fly genome. "The sequence data is good," Paul Gilman, a Celera vice president, claims. "The question is, 'How good is our assembly?'" That's a question that critics of the company's "whole genome shotgun" sequencing approach--blasting the entire genome into bits, then reassembling it, as opposed to the conventional "clone-by-clone" approach--have posed since the company announced its private sequencing attempts last summer.1

A complete and accurate Drosophila genome may mean different things to different people. "The successful assembly of the fly genome will validate the effectiveness of Celera's whole genome shotgun approach in deciphering complex genomes," J. Craig Venter, Celera's president and chief scientific officer, noted in a written statement. Francis Collins, director of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies